Announcement • May 14
PT Tempo Scan Pacific Tbk, Annual General Meeting, Jun 05, 2026 PT Tempo Scan Pacific Tbk, Annual General Meeting, Jun 05, 2026. Location: tempo scan tower, lt.16, jl. h. r. rasuna said kav, jakarta selatan kota adm. jakarta selatan dki., . jakarta indonesia, jakarta Indonesia Reported Earnings • May 05
First quarter 2026 earnings released: EPS: Rp78.00 (vs Rp91.00 in 1Q 2025) First quarter 2026 results: EPS: Rp78.00 (down from Rp91.00 in 1Q 2025). Revenue: Rp3.41t (up 4.2% from 1Q 2025). Net income: Rp351.8b (down 14% from 1Q 2025). Profit margin: 10% (down from 13% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 01
Full year 2025 earnings released: EPS: Rp312 (vs Rp321 in FY 2024) Full year 2025 results: EPS: Rp312 (down from Rp321 in FY 2024). Revenue: Rp14t (up 2.6% from FY 2024). Net income: Rp1.41t (down 2.8% from FY 2024). Profit margin: 10.0% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 04
Third quarter 2025 earnings released: EPS: Rp95.94 (vs Rp58.00 in 3Q 2024) Third quarter 2025 results: EPS: Rp95.94 (up from Rp58.00 in 3Q 2024). Revenue: Rp3.54t (up 4.8% from 3Q 2024). Net income: Rp434.1b (up 66% from 3Q 2024). Profit margin: 12% (up from 7.8% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Nov 03
Upcoming dividend of Rp100.00 per share Eligible shareholders must have bought the stock before 10 November 2025. Payment date: 25 November 2025. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 4.1%. Lower than top quartile of Indonesian dividend payers (5.3%). Higher than average of industry peers (2.8%). Board Change • Oct 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 10 non-independent directors. Independent Commissioner Suparni Setiono was the last independent director to join the board, commencing their role in 2016. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 16
PT Tempo Scan Pacific Tbk, Annual General Meeting, May 23, 2025 PT Tempo Scan Pacific Tbk, Annual General Meeting, May 23, 2025. Location: meeting both physically and eletronically, jakarta Indonesia Reported Earnings • Nov 01
Third quarter 2024 earnings released: EPS: Rp58.00 (vs Rp57.12 in 3Q 2023) Third quarter 2024 results: EPS: Rp58.00 (up from Rp57.12 in 3Q 2023). Revenue: Rp3.37t (up 2.9% from 3Q 2023). Net income: Rp261.7b (flat on 3Q 2023). Profit margin: 7.8% (down from 7.9% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to Rp2,800, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 135% over the past three years. Reported Earnings • Aug 01
Second quarter 2024 earnings released: EPS: Rp92.01 (vs Rp27.67 in 2Q 2023) Second quarter 2024 results: EPS: Rp92.01 (up from Rp27.67 in 2Q 2023). Revenue: Rp3.34t (up 2.5% from 2Q 2023). Net income: Rp413.6b (up 233% from 2Q 2023). Profit margin: 12% (up from 3.8% in 2Q 2023). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 16% per year. Buy Or Sell Opportunity • May 21
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at Rp2,020. The fair value is estimated to be Rp2,541, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 18%. Reported Earnings • May 02
First quarter 2024 earnings released: EPS: Rp90.00 (vs Rp126 in 1Q 2023) First quarter 2024 results: EPS: Rp90.00 (down from Rp126 in 1Q 2023). Revenue: Rp3.44t (up 6.4% from 1Q 2023). Net income: Rp407.4b (down 28% from 1Q 2023). Profit margin: 12% (down from 18% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 29
Full year 2023 earnings released: EPS: Rp261 (vs Rp222 in FY 2022) Full year 2023 results: EPS: Rp261 (up from Rp222 in FY 2022). Revenue: Rp13t (up 7.1% from FY 2022). Net income: Rp1.18t (up 18% from FY 2022). Profit margin: 9.0% (up from 8.2% in FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 21
Now 21% undervalued Over the last 90 days, the stock has risen 14% to Rp2,010. The fair value is estimated to be Rp2,541, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.2% over the last 3 years. Earnings per share has grown by 23%. Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: Rp57.12 (vs Rp35.99 in 3Q 2022) Third quarter 2023 results: EPS: Rp57.12 (up from Rp35.99 in 3Q 2022). Revenue: Rp3.28t (up 4.2% from 3Q 2022). Net income: Rp259.3b (up 60% from 3Q 2022). Profit margin: 7.9% (up from 5.1% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: Rp27.67 (vs Rp24.01 in 2Q 2022) Second quarter 2023 results: EPS: Rp27.67 (up from Rp24.01 in 2Q 2022). Revenue: Rp3.25t (up 9.6% from 2Q 2022). Net income: Rp124.1b (up 14% from 2Q 2022). Profit margin: 3.8% (up from 3.6% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to Rp1,920, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 66% over the past three years. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to Rp1,785, the stock trades at a trailing P/E ratio of 6.2x. Average trailing P/E is 21x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders of 62% over the past three years. Reported Earnings • Apr 30
First quarter 2023 earnings released: EPS: Rp126 (vs Rp60.12 in 1Q 2022) First quarter 2023 results: EPS: Rp126 (up from Rp60.12 in 1Q 2022). Revenue: Rp3.23t (up 8.8% from 1Q 2022). Net income: Rp568.8b (up 110% from 1Q 2022). Profit margin: 18% (up from 9.1% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: No independent directors. 9 non-independent directors. Independent Commissioner Phillips Gunawan was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 10 non-independent directors. Independent Commissioner - Kustantinah was the last independent director to join the board, commencing their role in 2012. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 05
Full year 2021 earnings released Full year 2021 results: EPS: Rp183. Revenue: Rp11t (up 2.4% from FY 2020). Net income: Rp823.8b (up 4.6% from FY 2020). Profit margin: 7.3% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 05
Second quarter 2021 earnings released: EPS Rp27.23 (vs Rp19.26 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Rp2.74t (up 5.9% from 2Q 2020). Net income: Rp122.5b (up 41% from 2Q 2020). Profit margin: 4.5% (up from 3.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment deteriorated over the past week After last week's 20% share price decline to Rp1,650, the stock is trading at a trailing P/E ratio of 11.8x, down from the previous P/E ratio of 14.6x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 8.4%. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment improved over the past week After last week's 40% share price gain to Rp1,990, the stock is trading at a trailing P/E ratio of 14.2x, up from the previous P/E ratio of 10.1x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years are 27%. Is New 90 Day High Low • Jan 07
New 90-day high: Rp1,565 The company is up 23% from its price of Rp1,275 on 09 October 2020. The Indonesian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Valuation Update With 7 Day Price Move • Dec 09
Market bids up stock over the past week After last week's 18% share price gain to Rp1,540, the stock is trading at a trailing P/E ratio of 11x, up from the previous P/E ratio of 9.3x. This compares to an average P/E of 23x in the Pharmaceuticals industry in Indonesia. Total returns to shareholders over the past three years were flat. Is New 90 Day High Low • Dec 08
New 90-day high: Rp1,390 The company is up 7.0% from its price of Rp1,295 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Reported Earnings • Nov 04
Third quarter 2020 earnings released: EPS Rp27.64 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: Rp2.74t (down 2.7% from 3Q 2019). Net income: Rp124.9b (up 46% from 3Q 2019). Profit margin: 4.6% (up from 3.0% in 3Q 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.